
November 12, 2025

To,
Listing Department,
National Stock Exchange Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400 051

Scrip Code - INFLUX

Dear Sir/Madam,

Sub.: Outcome of Board Meeting

Ref.: Regulation 30 of SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015.

In continuation of our intimation dated October 29, 2025, we wish to inform you that the Board of Directors of the Company, at its meeting held today, November 12, 2025, has:

1. Approved the Unaudited Standalone Financial Results of the Company for the half year ended September 30, 2025 .
2. Taken note that the Statutory Auditors have carried out a Limited Review of the aforementioned financial results, in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. Taken note of Certificate of Utilization of Issue Proceeds certified by Statutory Auditor for the half year ended September 30, 2025.

Accordingly, please find enclosed herewith a copy of the Unaudited Financial Results along with Limited Review Report of the Company and Certificate of Utilization of Issue Proceeds for the half year ended September 30, 2025.

The Board Meeting commenced at 10:30 AM and concluded at 12:00 PM.

We request you to kindly take the above information on record.

Thanking you,
For Influx Healthtech Limited,

Munir Abdul Ganee Chandniwala
Managing Director
DIN: 08459582

V. B. Goel & Co
Chartered Accountants

Simba Tower, 6th Floor,
Vishveshwar Nagar,
Goregaon (East), Mumbai - 400 063
☎ +91 22 28441350/35174263/46030191
✉ info@vbgco.com
Website: www.vbgco.com

Independent Auditor's Limited Review Report on unaudited financial results of Influx Healthtech Limited for the half year ended September 30, 2025 pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Influx Healthtech Limited

We have reviewed the accompanying Statement of Unaudited Financial results ('the Statement') of **INFLUX HEALTHTECH LIMITED** ("the Company") for the half year ended September 30, 2025 for the period from April 01, 2025 to September 30, 2025 being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations"), including the relevant circulars issued by SEBI from time to time.


This statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in applicable Accounting Standard 25, Interim Financial Reporting, specified under Section 133 of the Companies Act 2013, read with relevant rules issued thereunder, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our Responsibility is to express a conclusion on the Statement based on our review of the Statement.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of Interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Based on our review conducted and procedures performed as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards, specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The Figures for the half year ended March 31, 2025 are the balancing figures between Audited Figures in respect of the full financial year and the year to date figures upto the half year ended September 30, 2024, which were not subjected to limited review by us. Our opinion on the Statement is not modified in respect of this matter.



FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

WZ

(Vikas Goel)
Partner

Membership No: 039287

UDIN: 25039287 BM1JW X 1319

Place: Mumbai
Date: 12/11/2025

**STATEMENT OF UNAUDITED AUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED ON
30TH SEPTEMBER, 2025**

(All amount in Rs. Lakhs, unless otherwise stated)

Sr. No.	Particulars	Half Year Ended			For the year Ended
		30.09.2025	31.03.2025	30.09.2024	31.03.2025
		Un-Audited	Un-Audited	Un-Audited	Audited
1	Income				
a.	Revenue from Operations	6,676.46	5,679.39	4,805.97	10,485.36
b.	Other Income	9.46	10.62	2.69	13.31
	Total Income	6,685.92	5,690.01	4,808.66	10,498.67
2	Expenses				
a.	Cost of Material Consumed	3,909.49	3,368.85	2,971.94	6,340.78
b.	Changes in inventories of Finished Goods	(155.55)	0.89	0.27	1.16
c.	Employee Benefit Expenses	508.94	488.36	391.08	879.45
d.	Finance Cost	0.10	0.17	16.42	16.60
e.	Depreciation & Amortization	168.33	156.56	125.88	282.45
f.	Other Expenses	947.38	673.96	532.87	1,206.83
	Total Expenses	5,378.69	4,688.79	4,038.46	8,727.27
3	Total Profit/(Loss) Before Exceptional Items and Tax	1,307.24	1,001.22	770.20	1,771.40
4	Exceptional Items	-	-	-	-
5	Total Profit / (Loss) Before Tax	1,307.24	1,001.22	770.20	1,771.40
6	Tax Expense				
a.	Current Tax	345.38	245.62	195.38	440.99
b.	Deferred Tax	(39.42)	(9.40)	19.72	10.32
c.	Short/(Excess) Provision for Earlier years	-	-	(7.22)	(7.22)
7	Total Tax Expenses	305.96	236.22	207.88	444.09
8	Net Profit/(Loss) for a period (5-7)	1,001.28	765.00	562.32	1,327.31
9	Profit/(Loss) for The Period from discontinued operations before tax	-	-	-	-
10	Tax Expense of discontinued operations	-	-	-	-
11	Net Profit/(Loss) from discontinued operation after tax (9-10)	-	-	-	-
12	Net Profit/(Loss) for the year	1,001.28	765.00	562.32	1,327.31
	Paid up Equity Share Capital (Face value of Rs. 10/- each)	2,315.04	1,815.00	1,815.00	1,815.00
13	Earnings per share				
a.	Basic (in Rs.)	4.81	4.21	3.10	7.31
b.	Diluted (in Rs.)	4.81	4.21	3.10	7.31

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M.A. Chandniwala

Munir Chandniwala
(Managing Director)

DIN : 08459582

Place: Mumbai

Date: 12/11/2025


[Signature]

Notes to standalone financial results for the Half Year Ended 30th September, 2025

- 1 The above results have been prepared as per Generally Accepted Accounting Principles in India, prescribed u/s section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in accordance with the recognition and measurement principles laid down in Accounting Standard 25 (Interim Financial Reporting), as applicable, specified in Section 133 of the Companies Act, 2013 read with relevant rules framed thereunder or as specified by the Institute of Chartered Accountants of India, whichever is applicable.
- 2 The above results for the half year ended September 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 10, 2025
- 3 The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
- 4 Since there are no separate reportable business segments, the disclosure requirements as per AS 17 "Segment Reporting" are not applicable.
- 5 The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share in accordance with the Accounting Standard 20.
- 6 The basic and diluted EPS for the half year ended Sep 30 2025, Mar 31 2025 and Sep 30 2024 are not annualised.
- 7 Previous period figures have been re-grouped and re-classified wherever necessary.
- 8 There were no investor complaints known to the Company outstanding at the beginning and at the end of the quarter ended on September 30, 2025.
- 9 As the Company is listed on SME Emerge platform of National Stock Exchange of India Limited, the requirement of submitting "year to date" financial result is not applicable under Regulation 33(5) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.
- 10 The standalone financial results pertaining to the half year ended September 30, 2024 and March 31, 2025 have not been subject to limited review or audit and have been presented based on the information compiled by the Management. The Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs in accordance with the Accounting Standards (AS).
- 11 The results of the Company are also available for investors at www.influxhealthtech.com
- 12 The company has completed fresh issue of Equity Shares by Initial Public Offer ("IPO") of 50,00,400 Equity Shares of face value Rs.10 each at an issue price of Rs. 96 per equity share. The Equity Shares of the company were listed on National Stock Exchange of India Limited ("NSE") Emerge Platform on June 25, 2025. The details of utilization of the net proceeds as mentioned below:

Sr No.	Objects as disclosed in the offer document	Amount disclosed in offer document	Amount utilized upto 30.09.2025	Unutilized amount as on 30.09.2025
1	Funding Capital expenditure requirements for setting up of manufacturing facilities	3,673.34	405.15	3,268.19
2	General Corporate Purpose	667.40	574.12	93.28
3	Public Issue Expenses	583.24	583.24	-
	Total	4,923.98	1,562.51	3,361.47

For and on the behalf of Board of Directors of
Influx Healthtech Limited


Munir Chandniwala
(Managing Director)
DIN : 08459582
Place: Mumbai
Date: 12/11/2025



STATEMENT OF ASSETS AND LIABILITIES AS ON SEPTEMBER 30, 2025

(All amount in Rs. Lakhs, unless otherwise stated)

Particulars	As at	As at
	30-09-2025	31-03-2025
	Un-Audited	Audited
I EQUITY AND LIABILITIES		
(1) Shareholders' fund		
Share Capital	2,315.04	1,815.00
Reserves and Surplus	6,708.07	1,799.55
Total Shareholders Fund	9,023.11	3,614.55
(2) Non-Current Liabilities		
Long term borrowings	-	-
Deferred Tax Liabilities (Net)	-	-
Other Long Term Liabilities	-	5.26
Long Term Provisions	1.73	17.73
Total Non-Current Liabilities	1.73	22.98
(3) Current Liabilities		
Short Term Borrowings	-	21.92
Trade Payables	1,930.18	2,941.95
Other Current Liabilities	250.95	271.03
Short Term Provisions	148.05	157.48
Total Current Liabilities	2,329.18	3,392.38
Total Equity and Liabilities	11,354.02	7,029.91
II ASSETS		
(1) Non-Current Assets		
(i) Property Plant & Equipment and Intangible Assets		
Property Plant & Equipment	2,418.10	1,872.50
Intangible Assets	3.32	3.81
Capital work-in-progress	55.48	-
Intangible Assets under development	-	-
Total Property, Plant & Equipments	2,476.90	1,876.31
(ii) Non-Current Investments	-	-
(iii) Deferred tax assets (net)	57.67	18.25
(iv) Long-term loans and advances	563.60	183.39
(v) Other non-current assets	-	50.00
Total Non-Current Assets	3,098.17	2,127.95
(2) Current Assets		
Current Investments	3,368.28	-
Inventories	1,062.86	1,321.73
Trade Receivables	3,409.88	3,244.09
Cash & Cash Equivalents	201.30	191.00
Short-term loans and advances	109.34	76.30
Other current assets	17.59	68.12
Total Current Assets	8,255.85	4,901.96
TOTAL ASSETS	11,354.02	7,029.91

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M. A. Chandniwala

Munir Chandniwala
(Managing Director)
DIN : 08459582
Place: Mumbai
Date: 12/11/2025

[Signature]

STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER, 2025

(All amount in Rs. Lakhs, unless otherwise stated)

Sl.	Particulars	For the half year ended 30.09.2025 Un-Audited	For the year ended 31.03.2025 Audited
A)	Cash Flow from Operating Activities		
	Net Profit before tax & extraordinary items	1,307.24	1,771.41
	Adjustment For :		
	Depreciation & Amortization Expenses	168.33	282.45
	Bad Debts Written Off	-	8.49
	Provision for bad and doubtful debts	44.93	-
	Reversal of Doubtful Debts (net of provision)	-	(4.00)
	Sundry Balance Writen Back	(1.61)	-
	Interest Expenses & other finance cost	0.10	16.60
	Interest Income	(0.69)	(5.62)
	Income from investments	(6.73)	-
	Operating Profit Before Working Capital Changes	1,511.57	2,069.32
	Adjusted for :		
	Increase/(Decrease) in Trade payables	(1,010.17)	1,543.92
	Increase/(Decrease) in Other Current Liabilities	2.75	59.69
	Increase/(Decrease) in Provision	(15.99)	(10.94)
	(Increase)/Decrease in Other liabilities	(5.26)	-
	(Increase)/Decrease in Trade Receivables	(210.72)	(1,656.99)
	(Increase)/Decrease in Inventories	258.87	(776.11)
	(Increase)/Decrease in Loans and Advances	(37.34)	(11.64)
	(Increase)/Decrease in Other Current and Non-current Assets	(16.52)	(67.45)
	Net Cash generated from Operating activities (before tax)	477.19	1,149.80
	(Tax Paid)/ Tax Refund - Net	(354.91)	(444.18)
	Net Cash Generated from Operating Activities (A)	122.28	705.62
B)	Cash Flow from Investing Activities		
	Purchase of Property, Plant and Equipment and Intangible Assets	(1,167.40)	(821.11)
	Investment in Securities	(3,361.55)	-
	Maturity of fixed deposit	50.00	(50.00)
	Interest Income	0.69	6.64
	Net Cash used in Investment Activities (B)	(4,478.26)	(864.47)
C)	Cash Flow from Financing Activities		
	Proceeds from Initial Public Offer (net of issue expenses)	4,474.74	-
	Interest Expenses & other finance cost	-	(0.09)
	(Repayment)/ Proceeds of Short Term Borrowings	(21.92)	(10.56)
	Net cash generated from / (used in) Financing Activities (C)	4,452.82	(10.66)
	Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	96.84	(169.50)
	Cash and Cash Equivalents at the beginning of the Year		
	Cash and cash equivalents	191.06	290.56
	Short term bank deposits	-	70.00
	Cash and cash equivalents at the end of the Year	287.90	191.06
	Cash and cash equivalents comprise of:		
	Cash on Hand	3.78	0.94
	Bank Balances:		
	In Current Accounts	284.12	190.13
	Short Term Bank Deposit	-	-
	Cash and cash equivalents at the end of the Year	287.90	191.06

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M. A. Chandniwala

Munir Chandniwala
(Managing Director)
DIN : 08459582
Place: Mumbai
Date: 12/11/2025

[Signature]

To,
The Board of Directors
Influx Healthtech Limited

We, the statutory auditors of Influx Healthtech Limited having registered office at 109, Ghanshyam Enclave Premises Co-op Soc, Plot No. 856, Laljipada, Kandivali West, Mumbai - 400067 have verified the books of accounts of the Company and other relevant records produced before us. On the basis of such verification and according to information and explanations given to us, we confirm that the company has incurred the following expenditure from the utilization of issue proceeds.

(Rupees in Lakhs)

Sr. No.	Objects as disclosed in the Offer document	Amount disclosed in the Offer document	Actual Utilized Amount upto 30.09.2025	Unutilized Amount as on 30.09.2025
1	Funding Capital expenditure requirements for setting up of manufacturing facilities	3,673.34	405.15	3,268.19
2	General Corporate Purpose	667.40	574.12	93.28
3	Public Issue Expenses	583.24	583.24	-
Total		4,923.98	1,562.51	3,361.47

This Certificate is intended for your information or to be provided to any entity or Regulatory Authority in connection with the utilization of issue proceeds and is not to be used, referred to or distributed for any other purpose without our written consent.



Place: Mumbai
Date: 12/11/2025

FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

(Vikas Goel)
Partner
Membership No: 039287
UDIN: 25039287BMIJWY4060